EFGCP Switches Annual Congress from January to March
The European Forum for GCP (EFGCP) has moved its annual two-day conference from the traditional slot in late January to the beginning of March.
Under the title of “Bringing together the two worlds of medicine & device research to better serve public, patients & research participants,” EFGCP Annual Conference 2016 will take place on March 1 and 2, in Brussels, Belgium.
The aim of the event is to help the two worlds of pharma and medical devices develop research, medicines and equipment for patient benefit.
“The EU Medical Device regulations are almost upon us. These will have significant consequences, similar to the Clinical Trail Regulations and there is an opportunity to learn from pharma experience,” noted EFGCP in a statement issued October 1.
The meeting will outline what regulations will mean to the devices industry and focus on the lessons learnt from experience with the clinical trial regulations. The tangible outcomes will be an EFGCP report and recommendations that will be provided to those involved in the legislative process.
For 22 years the European Forum for Good Clinical Practice has acted as a forum to bring patients, researchers, sponsors, competent authorities and ethics committees together and debate current topics. It is recognized as an important forum for multi-stakeholder debate.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
